We believe that our data clearly demonstrate an unexplored mechanism of tumor-induced osteolysis in BM patients and further validate the use of TCZ, or IL-6 and IL-8 inhibitors to treat BM, especially for those patients with high circulating level of these cytokines, or high FDG-PET uptake that would imply a high tumor glycolytic rate and, thus, high intratumoral acidosis (Longo et al., 2016). This evidence concerns the gene CXCL8 and neoplasm.